Wells Fargo & Company Beyond Spring Inc. Transaction History

Wells Fargo & Company

$468 Billion
Q2 2025

A detailed history of Wells Fargo & Company transactions in Beyond Spring Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 175,000 shares of BYSI stock, worth $309,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares

175,000

Holding current value

$309,750

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.06 - $3.05 $2,120 - $6,100	-2,000 Reduced 77.52%	580 $0
Q4 2022 Feb 13, 2023	BUY	$0.56 - $2.61 $1,120 - $5,220	2,000 Added 344.83%	2,580 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $533 - $995	-550 Reduced 48.67%	580 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.13 - $2.66 $14,826 - $34,901	-13,121 Reduced 92.07%	1,130 $2,000
Q1 2022 May 16, 2022	BUY	$1.68 - $5.01 $1,461 - $4,358	870 Added 6.5%	14,251 $31,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $33,848 - $141,792	8,420 Added 169.72%	13,381 $61,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $22,409 - $75,770	2,420 Added 95.24%	4,961 $78,000
Q2 2021 Aug 16, 2021	SELL	$9.37 - $12.12 $54,477 - $70,465	-5,814 Reduced 69.59%	2,541 $27,000
Q1 2021 May 13, 2021	SELL	$10.61 - $15.77 $368,464 - $547,660	-34,728 Reduced 80.61%	8,355 $92,000
Q4 2020 Feb 09, 2021	BUY	$10.21 - $17.31 $3,971 - $6,733	389 Added 0.91%	43,083 $526,000
Q3 2020 Nov 05, 2020	SELL	$9.99 - $16.13 $34,435 - $55,600	-3,447 Reduced 7.47%	42,694 $569,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $160,258 - $259,472	14,296 Added 44.89%	46,141 $695,000
Q1 2020 May 14, 2020	BUY	$9.68 - $18.47 $308,259 - $588,177	31,845 New	31,845 $408,000

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.61M

Call Options Held

288K

Put Options Held

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.9M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account